HOME >> MEDICINE >> NEWS
Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration

NEW ORLEANS, October 21, 2004 -- Eyetech Pharmaceuticals, Inc. (Nasdaq: EYET) today announced that the treatment effect with the investigational drug Macugen (pegaptanib sodium injection) extends for two years in patients with neovascular or wet, age-related macular degeneration (AMD), who are at risk of losing their vision. A treatment benefit was also seen for patients who received Macugen for two years compared to those only receiving one year of therapy.

The data confirm that patients benefit from two years of treatment with Macugen for wet AMD. The second year data for Macugen will be presented by Anthony P. Adamis, M.D., Chief Scientific Officer, Eyetech Pharmaceuticals and Steven Schwartz, M.D., Chief, Retina Division, Jules Stein Eye Institute, University of California, Los Angeles, at the Retina Subspecialty symposium of the American Academy of Ophthalmology Meeting on Friday, October 22, 2004 at 8:00 a.m. Central Time and 10:38 a.m. Central Time respectively.

Eyetech and Pfizer are partnering to develop and market Macugen, a treatment for neovascular or wet AMD, the leading cause of severe vision loss in patients older than 50 years of age in the developed world. Eyetech and Pfizer have filed an NDA for Macugen for neovascular AMD with the FDA. Macugen has been assigned priority review status and the PDUFA date is December 17, 2004.

"We are excited about the new data because they confirm that treatment with Macugen is effective in patients with neovascular AMD who are at risk of losing their vision," said David R. Guyer, M.D., Chief Executive Officer, Eyetech Pharmaceuticals. "The two year data on Macugen demonstrate that longer term use may be beneficial for patients suffering from this chronic disease."

These data are from two, pivotal Phase II/III randomized, multi-center, double-masked studies in patients with all subtypes of neovascular AMD. 1,186 patients were initially randomized to receive one
'"/>


21-Oct-2004


Page: 1 2 3

Related medicine news :

1. The Gerontological Society of America announces Hartford Fellowship recipients
2. TB Alliance announces new drug discovery program with GlaxoSmithKline
3. ASGE announces grant recipients in annual research awards program
4. Novartis announces collaboration with Bayer for EMSELEX
5. American College of Chest Physicians announces new Critical Care Institute
6. Department of Energy announces new agreement with USC, national labs and private company
7. ACP announces international medical fellowship
8. St. Jude Medical announces CRT patients showed improvement in the RHYTHM ICD study
9. St. Jude Medical announces PAVE and DINAMIT clinical trial results
10. National Inventors Hall of Fame announces 2004 class of inventors
11. Joslin announces first international affiliate in Bahrain

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/11/2018)... ... ... Dr. Siavash Eftekhari, Oral and Maxillofacial Surgeon at Monarch Dental® in ... to deliver dental care in impoverished communities. Along with a team of fellow ... to help deliver care to over 550 individuals in need. , This outreach was ...
(Date:8/11/2018)... ATLANTA (PRWEB) , ... August 11, 2018 , ... ... winner of a Silver Stevie® Award in the Executive of the Year-Business category ... the world’s premier business awards program. All individuals and organizations worldwide – public ...
(Date:8/9/2018)... ... August 09, 2018 , ... ... by simplifying medication adherence monitoring with Smart-pill bottle and mobile applications, DoseSmart ... the App Orchard. , The DoseSmart medication management and medication adherence platform ...
(Date:8/7/2018)... ... August 07, 2018 , ... Sussex Vision Center, a multi-site optometry practice ... Sussex, OD, founded the practice in Coldwater, and over the last three decades has ... to offer comprehensive eye health services for patients of all ages. , “I ...
(Date:8/3/2018)... ... August 03, 2018 , ... On August 2, 2018 ... proceedings. Mark Sadaka of Sadaka Associates, LLC has been litigating Zostavax injuries ... before the Judicial Panel on Multidistrict Litigation for the thousands of people injured by ...
Breaking Medicine News(10 mins):
(Date:8/3/2018)... ... August 03, 2018 , ... Flexefits, a pioneer in direct -pay, direct access ... allowing participants in Direct Primary Care arrangements to keep HSA eligibility and permit DPC ... individual and $300 per family per month.) , “We are very pleased to see ...
(Date:8/2/2018)... ... ... UMD Professor Utpal Pal leads a team of investigators across multiple institutions ... of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), ... contribute to the spread of major diseases like Lyme disease. Pal is the project ...
(Date:8/2/2018)... ... August 02, 2018 , ... ... with customer relationship management (CRM), patient experience and provider communication solutions for ... Program for Health Information Service Providers (HISPs). DirectTrust is a ...
Breaking Medicine Technology:
Cached News: